'''PharmaMar''' is a pharmaceutical company based in [[Madrid]], [[Spain]]. It uses marine resources to develop drugs for cancer and Alzheimer's treatments. It is also involved in molecular testing, including COVID-19 testing, and genetic analysis. Its subsidiary, Sylentis, develops therapies that use RNA interference. < ref > {{Cite news|date=2015-02-26|title=BRIEF-Zeltia to propose reverse merger with PharmaMar|language=en|work=Reuters|url=https://www.reuters.com/article/idUSFWN0W004R20150226|access-date=2023-03-14}} < /ref >  The company is listed on the Madrid Stock Exchange and is part of the IBEX 35. < ref > {{Cite web|title=I.G.B.M {{!}} Precios sesi√≥n Bolsa de Madrid|url=https://www.bolsasymercados.es/bme-exchange/es/Mercados-y-Cotizaciones/Acciones/Mercado-Continuo/Precios/igbm-ES0SI0000609|access-date=2023-03-14|website=BME Exchange|language=es}} < /ref > 
 
 == References == 
 < references / > 
 
 [[Category:Manufacturing companies of Spain]] 
 [[Category:Pharmaceutical companies of Europe]]